1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharma Wholesale and Distribution Industry and Market: World Outlooks and Forecasts 2014-2024

Report Details

Trends and revenue potentials for distributing and wholesaling of medicines
Where’s the drug wholesaler and distribution (W&D) market heading? Discover revenue predictions there to 2024. Also find trends in business and technology, assessing prospects and opportunities to help your work and benefit your influence.

In visiongain’s new report you gain sales forecasts there at overall world market, submarket, company and national level. That study’s purpose is to let you hear what’s happening. There you assess potential for expanding revenues. See where that industry’s best prospects lie.

Read on, then, to explore drug distribution and discover what its future could be worth.

Forecasts and other analysis to benefit your knowledge of pharma W&D

Is finding data a challenge? Avoid falling behind for supply of medicines. You can now stay ahead in information, benefiting your research, analyses and decisions. Also save time.

Besides revenue forecasting, our new work shows historical data, growth rates and market shares. You discover original quantitative and qualitative analyses, getting feel for business outlooks and developments. You also gain 100 charts, 88 tables and two interviews.

There you investigate the supply chain for human medicine’s future. You find what’s happening and see where the money exists. Hear, too, where those gains can increase.

And the following sections highlight what our new investigation gives you.

Prospects for that world market and submarkets – discover what gains are possible

Our new report shows revenue to 2024 for the overall world market. It also shows you individual forecasts for three submarkets:
- Original-branded pharmaceuticals – small molecules and biological agents (biologics)
- Generic prescription drugs (generics)
- Other medicine.

How will the pharmaceutical wholesale and distribution (W&D) market grow? Which parts will most prosper and why? There you assess potential sales and revenue growth.

Also our study discusses what stimulates and restrains storing and distributing of drugs. That analysis helps you identify potential and find ways for your business to expand.

You also discover geographical revenue predictions.

Sales potentials for medical wholesale and distribution in leading countries

Developments worldwide expand the pharma W&D market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.

In developed and developing countries, opportunities for drug wholesalers and other medical suppliers will occur from 2014. Pharmacies also stand to benefit. See where, why and how.

Our report shows you individual revenue forecasts to 2024 for 11 national markets:
- United States (US)
- Japan
- Germany, France, United Kingdom (UK), Italy and Spain (EU5 countries)
- Brazil, Russia, India and China (BRIC nations).

There you discover progress and outlooks. You assess the W&D industry’s future, seeing developments and finding their significance.

That analysis shows highest revenue growth to 2024 will occur in developing countries. Developed markets will expand too. You investigate, also finding top companies’ potentials.

Sales forecasting and other information on leading firms

How will prominent companies perform to 2024 at world level? Our work shows you individual revenue forecasts for 10 wholesalers and distributors, including these:
- McKesson
- Cardinal Health
- AmerisourceBergen
- Alliance Boots
- Medipal
- PHOENIX Group.

There you assess those organisations, seeing activities, results, changes and outlooks. You find what’s happening, understanding trends, competition, challenges and opportunities.

That way you assess the future, discovering progress and finding its meaning. Our anal

Table Of Contents

Pharma Wholesale and Distribution Industry and Market: World Outlooks and Forecasts 2014-2024
1. Report Overview
1.1 The Global Pharma Wholesale and Distribution Industry and Market Review
1.2 The Global Pharma Wholesale and Distribution Industry Structure
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Analytical Report
1.6 Who is This Study For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistics Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribute a Large Amount of Products to Generate High Profit
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generating Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clearer Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market, 2014-2024
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2013, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution: World Market Forecast, 2014-2024
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2014-2024
3.3.1 Branded and Generic Drugs: Revenue Generation, 2013
3.3.2 Branded Drugs, Generic Drugs and Others: Revenue Forecasts, 2014-2024
3.3.3 Branded Drugs: Revenue Forecast, 2014-2024
3.3.4 Generic Drugs: Revenue Forecast, 2014-2024

4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2014-2024
4.1 Leading National Markets: The US Dominated in 2013
4.2 Leading National Markets: Revenue The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.3 An Increase in Fee-For-Service Activity
4.3.4 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2014-2024
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 Differences Between the US and Europe
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2014-2024
4.4.4 Germany: Pharma Wholesale and Distribution Market, 2013
4.4.4.1 Healthcare Reform
4.4.4.2 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.4.4.3 Germany Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.4.5 France: Pharma Wholesale and Distribution Market, 2013
4.4.5.1 France: Social Security Finance Bill 2014
4.4.5.2 France: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.4.6 Italy: Pharma Wholesale and Distribution Market, 2013
4.4.6.1 Italy: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.4.7 Spain: Pharma Wholesale and Distribution Market, 2013
4.4.7.1 Spain: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.4.8 UK: Pharma Wholesale and Distribution Market, 2013
4.4.8.1 Price Cuts in the UK
4.4.8.2 UK: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.5 Japan: Pharma Wholesale and Distribution Market, 2013
4.5.1 Drug Pricing and Performing Fees in Japan
4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.6 China: Pharma Wholesale and Distribution Market, 2013
4.6.1 China: Leading Pharma Wholesale and Distribution Companies, 2013
4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.7 Brazil: Pharma Wholesale and Distribution Market, 2013
4.7.1 Drug Price Controls in Brazil
4.7.2 Brazil: Leading Pharma Wholesale and Distribution Companies, 2013
4.7.3 Brazil: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.8 India: Pharma Wholesale and Distribution Market, 2013
4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.9 Russia: Pharma Wholesale and Distribution Market, 2013
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends in Russia
4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2014-2024
4.10 Conclusion

5. Leading Pharma Wholesalers and Distributors in 2014: Current and Future Performance
5.1 The Leading Wholesale and Distribution Companies in 2013
5.2 Revenue vs. Profit
5.3 Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2014-2024
5.4 McKesson: The Oldest and Largest Healthcare Services Company in the US
5.4.1 McKesson: Historical Performance, 2008-2013
5.4.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
5.4.3 McKesson: Revenue Forecast, 2014-2024
5.5 Cardinal Health: The World's Second Largest Pharma Wholesaler
5.5.1 Cardinal Health: Historical Performance, 2008-2013
5.5.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
5.5.3 Cardinal Health: Revenue Forecast, 2014-2024
5.6 AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor
5.6.1 AmerisourceBergen: Historical Performance, 2008-2013
5.6.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
5.6.3 AmerisourceBergen: Revenue Forecast 2014-2024
5.7 Alliance Boots: The Largest European Wholesaler
5.7.1 Alliance Boots: Historical Performance, 2008-2013
5.7.2 Future Strategies of Alliance Boots: Merger Plan with Walgreens to Become the Largest Provider of Healthcare Services
5.7.3 Alliance Boots: Revenue Forecast, 2014-2024
5.8 MEDIPAL HOLDINGS CORPORATION: Japan's Leading Pharmaceutical Wholesaler
5.8.1 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2008-2013
5.8.2 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
5.8.3 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2014-2024
5.9 The PHOENIX Group: Second Biggest Wholesaler in Europe
5.9.1 The PHOENIX Group: Historical Performance, 2008-2013
5.9.2 Future Strategies of the PHOENIX Group: Selective Acquisitions
5.9.3 The PHOENIX Group: Revenue Forecast, 2014-2024
5.10 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
5.10.1 SINOPHARM: Historical Performance, 2008-2013
5.10.2 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
5.10.3 SINOPHARM: Revenue Forecast, 2014-2024
5.11 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
5.11.1 Alfresa Holdings: Historical Performance, 2008-2013
5.11.2 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
5.11.3 Alfresa Holdings: Revenue Forecast, 2014-2024
5.12 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
5.12.1 SUZUKEN CO., LTD: Historical Performance, 2008-2013
5.12.2 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
5.12.3 SUZUKEN CO., LTD: Revenue Forecast, 2014-2024
5.13 Shanghai Pharmaceuticals Holding: China's Second Largest Wholesaler
5.13.1 Shanghai Pharmaceuticals Holding: Historical Performance, 2008-2013
5.13.2 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
5.13.3 Shanghai Pharma: Revenue Forecast, 2014-2024

6. Qualitative Analysis of the Pharma Wholesale and Distribution Market
6.1 Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2014
6.1.1 The Insatiable Demand for Drugs: A Recession-Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.2.1 Pre-Wholesaling: More Prevalent in Europe
6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.2. The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2014-2024
6.2.1The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
6.2.6.2 DTP in the UK Since 1991
6.2.6.3 DTP in Poland: The Second European Country to Adopt the DTP Model
6.2.6.4 Further Expansion of the DTP Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.7.1 Healthcare Budget Cuts in Germany
6.2.7.2 Healthcare Budget Cuts in France
6.2.7.3 Healthcare Budget Cuts in Italy
6.2.7.4 Healthcare Budget Cuts in Spain
6.2.7.5 Healthcare Budget Cuts in the UK
6.2.8 Do Large Pharmacy Chains Pose a Threat?
6.2.8.1 Case Study: Walmart and the $4.0 Prescription Scheme
6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
6.2.9 Does the Diversion and Re-importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economical and Political Factors Influencing the Market, 2014-2024 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
6.3.2.1 The US and E-Pedigree: Becoming Law in California
6.3.2.2 European Pedigree Legislation
6.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
6.2.3.4 Serialisation for Wholesalers: Opportunity or a Challenge?

7. Research Interviews
7.1 Interview with Mr Chris Frost, Sales Director of AAH Pharmaceuticals Ltd. (Celesio UK), Coventry
7.1.1 Current Status and Evolution of Pharma Wholesale and Distribution Market in the UK
7.1.2 Driving Factors of the Pharma Wholesale and Distribution Market in the UK
7.1.3 Future of the UK Pharma Wholesale and Distribution Market
7.1.4 Celesio UK Accounted for More Than 60% of the Group's Total Retail Pharmacy Business in 2013
7.1.5 The Outcome of McKesson's Acquisition of Celesio AG
7.1.6 Prominent Business Segments of Celesio AG in the Future
7.2 Interview with Dr Evelyn Walter, Co-Founder and Director of the Institute for Pharmaeconomic Research (IPF), Vienna
7.2.1 On Direct-to-Pharmacy Distribution
7.2.2 On the Effect of Drug Pricing Pressures on the Supply of Pharmaceuticals
7.2.3 On the Role of Pharmaceutical Wholesalers and Distributors in European Healthcare Systems
7.2.4 On the Impact of Counterfeit Drugs
7.2.5 On the Efficacy of the Pharmaceutical Wholesale and Distribution Industry

8. Conclusions from the Research and Analysis
8.1 The Future of the Pharma Wholesale and Distribution Market
8.2 The Leading National Pharma Wholesale and Distribution Markets
8.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
8.4 Trends in the Pharma Wholesale and Distribution Industry
8.4.1 Generics Will Threaten Revenue
8.4.2 Manufacturers Will Deliver More Drugs Directly
8.4.3 There Will Be Greater Demand for Specialty Medicines
8.4.4 Consolidation Will Drive Growth
8.4.5 Anti-Counterfeiting Demands Will Add to Wholesaler's Costs


List of Tables
Table 1.1 The Global Pharma Wholesale and Distribution Industry and Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Top Company, 2013-2024
Table 1.2 Foreign Currency Exchange Rates to $US, 2014
Table 2.1 Use of DTP Model in the UK, 2014
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market ($bn) Forecast, 2014-2024
Table 3.2 Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts and Market Shares (%), 2013-2024
Table 3.3 Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market (%) Forecast, 2014-2024
Table 3.4 Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market (%) Forecast, 2014-2024
Table 4.1 Pharma Wholesale and Distribution Leading National Markets: Revenues ($bn) and Market Shares (%), 2013
Table 4.2 Pharma Wholesale and Distribution Leading National Markets: Revenue Forecasts (%), 2013-2024
Table 4.3 Revenue and Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2013
Table 4.4 US Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.5 Price Controls in Europe, 2014
Table 4.6 EU5 Pharma Wholesale and Distribution Market: Revenue ($bn) Forecasts, 2014-2024
Table 4.7 German Pharma Wholesale and Distribution Market: Revenue ($bn), 2014-2024
Table 4.8 French Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.9 Italian Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.10 Spanish Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.11 UK Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.12 Percentage of the Population Ages 65+ in the US, Europe, Japan, China and India, 2025 and 2050
Table 4.13 Japanese Pharmaceutical Wholesale and Distribution Market: Historical Sales ($bn) and Drug Price Revision Growth (%), 2005-2012
Table 4.14 Japanese Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.15 Chinese Pharma Wholesale and Distribution: Revenue ($bn) and Market Shares (%) of Leading Companies, 2013
Table 4.16 Chinese Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.17 Brazilian Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.18 Indian Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 4.19 Russian Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Table 5.1 Leading Companies in the Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2013
Table 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), 2013-2024
Table 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2013-2024
Table 5.4 McKesson, Distribution Solutions: Services and Customers, 2014
Table 5.5 McKesson, Technology Solutions: Services and Customers, 2014
Table 5.6 McKesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2008-2013
Table 5.7 McKesson: Revenue ($bn), Gross Profit ($bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.8 McKesson: Revenue Share (%) and Gross Profit Share (%) Breakdown by Business Segment, 2012-2013
Table 5.9 McKesson: Pharmaceutical Distribution and Services Revenue ($bn) and Revenue Share (%) by Region, 2013
Table 5.10 Acquisitions by McKesson, 2007-2014
Table 5.11 McKesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 5.12 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%) 2008-2013
Table 5.13 Cardinal Health: Revenue ($bn) and Gross Profit ($bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.14 Cardinal Health: Revenue Share (%) and Gross Profit Share (%) Breakdown by Business Segment, 2012-2013
Table 5.15 Cardinal Health: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2013
Table 5.16 Valuable Acquisitions by Cardinal Health and their Line of Business, 2007-2014
Table 5.17 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 5.18 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%) 2008-2013
Table 5.19 AmerisourceBergen: Revenue ($bn) and Gross Profit ($bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.20 AmerisourceBergen: Revenue Share (%) and Gross Profit Share (%) Breakdown by Business Segment, 2012-2013
Table 5.21 AmerisourceBergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2013
Table 5.22 Acquisitions by AmerisourceBergen and their Line of Business, 2007-2013
Table 5.23 AmerisourceBergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 5.24 Alliance Boots: Historical Revenue (£bn, $bn), Revenue AGR (%), Revenue CAGR (%),Trading Profit (£bn, $bn), Trading Profit AGR (%) and Trading Profit CAGR (%), 2008-2013
Table 5.25 Alliance Boots: Revenue (£bn, $bn) and Trading Profit (£bn, $bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.26 Alliance Boots: Revenue Share (%) and Trading Profit Share (%) Breakdown by Business Segment, 2013
Table 5.27 Alliance Boots: Pharmaceutical Wholesale Revenue (£bn, $bn), Revenue Share (%) Breakdown by Country, 2013
Table 5.28 Alliance Boots: Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2014-2024
Table 5.29 MEDIPAL Holdings: Consolidated Subsidiary Companies, 2014
Table 5.30 MEDIPAL Holdings: Historical Revenue (Â¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (Â¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2008-2013
Table 5.31 MEDIPAL Holdings: Revenue (Â¥bn, $bn) and Operating Income (Â¥bn, $bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.32 MEDIPAL Holdings: Revenue Share (%) and Operating Income Share (%) Breakdown by Business Segment, 2012-2013
Table 5.33 MEDIPAL Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 5.34 PHOENIX Group: Subsidiary Companies, 2014
Table 5.35 PHOENIX Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2008-2013
Table 5.36 PHOENIX Group: Revenue (€bn, $bn), Revenue Share (%) Breakdown by Region, 2013
Table 5.37 PHOENIX Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 5.38 SINOPHARM Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2008-2013
Table 5.39 SINOPHARM Group: Revenue (RMBbn, $bn) and Operating Profit (RMBbn, $bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.40 SINOPHARM Group: Revenue Share (%) and Operating Profit Share (%) Breakdown by Business Segment, 2012-2013
Table 5.41 SINOPHARM Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 5.42 Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2014
Table 5.43 Alfresa Holdings: Set Targets and Results of the 10-12 Medium-term Management Plan - "Advancement and Expansion-Next Stage", 2013
Table 5.44 Alfresa Holdings: Historical Revenue (Â¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (Â¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2008-2013
Table 5.45 Alfresa Holdings: Sales launches in the Manufacturing Business Segment, 2013
Table 5.46 Alfresa Holdings: Revenue (Â¥bn) and Gross Profit (Â¥bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.47 Alfresa Holdings: Revenue Share (%) and Gross Profit Share (%) Breakdown by Business Segment, 2012-2013
Table 5.48: Alfresa Holdings: Targets of the 13-15 Medium-term Management Plan - The Challenge of Reform- Uniting to Climb New Peaks, 2014
Table 5.49 Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 5.50 SUZUKEN: Historical Revenue (Â¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (Â¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2008-2013
Table 5.51 SUZUKEN: Revenue (Â¥bn, $bn) and Profit (Â¥bn, $bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.52 SUZUKEN: Revenue Share (%) and Operating Income Share (%) Breakdown by Business Segment, 2012-2013
Table 5.53 SUZUKEN: Revenue (Â¥bn, $bn), Revenue Share (%) Breakdown by Region in Japan, 2013
Table 5.54 SUZUKEN: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 5.55 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2008-2013
Table 5.56 Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn) and Operating Profit (RMBbn, $bn) and AGR (%) Breakdown by Business Segment, 2012-2013
Table 5.57 Shanghai Pharmaceuticals Holding: Revenue Share (%) and Operating Profit Share (%) Breakdown by Business Segment, 2012-2013
Table 5.58 Shanghai Pharmaceuticals Holding: Distribution Revenue (RMBbn, $bn), Distribution Revenue Share (%) Breakdown by Region, 2013
Table 5.59 Shanghai Pharmaceuticals Holding: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2024
Table 6.1 The Pharmaceutical WandD Market: Strengths and Weaknesses, 2014
Table 6.2 The Pharmaceutical WandD Market: Opportunities and Threats, 2014-2024
Table 6.3 Strengths and Weaknesses of the DTP Distribution Model, 2014
Table 6.4 ITR Ratings and Corresponding Reimbursement Rates, 2014
Table 6.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (STEP Analysis), 2014-2024


List of Figures
Figure 1.1 Forecast Global Population Over the Age of 65 Years (millions), Annual Growth Rate (%), 2013-2024
Figure 1.2 Routes of Drug Distribution, 2014
Figure 2.1 Routes of Drug Distribution, 2014
Figure 3.1 The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 3.2 Pharmaceutical Wholesale and Distribution: World Market ($bn) Forecast, 2014-2024
Figure 3.3 Branded Drugs, Generic Drugs and Others: Markets Shares (%), 2013
Figure 3.4 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2018
Figure 3.5 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2024
Figure 3.6 Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecast ($bn), 2014-2024
Figure 3.7 Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2014-2024
Figure 3.8 Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2014-2024
Figure 4.1 Pharma Wholesale and Distribution Leading National Markets: Shares (%), 2013
Figure 4.2 Pharma Wholesale and Distribution Leading National Markets: Shares (%), 2018
Figure 4.3 Pharma Wholesale and Distribution Leading National Markets: Shares (%), 2024
Figure 4.4 Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2013
Figure 4.5 US Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.6 US Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.7 EU5 Pharma Wholesale and Distribution Market Shares (%), 2013, 2018 and 2024
Figure 4.8 EU5 Pharma Wholesale and Distribution Market: Revenue ($bn) Forecasts, 2013-2024
Figure 4.9 EU5 Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.10 German Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.11 German Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.12 French Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.13 French Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.14 Italian Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.15 Italian Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.16 Spanish Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.17: Spanish Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.18 UK Pharma Wholesale and Distribution Market: Revenue ($bn), 2014-2024
Figure 4.19 UK Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.20 Percentage of the Population Ages 65+ in the US, Europe, Japan, China and India, 2025 and 2050
Figure 4.21 Japanese Pharmaceutical Wholesale and Distribution Market: Historical Sales ($bn), 2005-2012
Figure 4.22 Japanese Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.23 Japanese Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.24 Chinese Pharma Wholesale and Distribution: Market Shares (%) of Leading Companies, 2013
Figure 4.25 Chinese Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.26 Chinese Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.27 Brazilian Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.28 Brazilian Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.29 Pharma Wholesale and Distribution Model in India, 2014
Figure 4.30 Indian Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.31 Indian Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 4.32 Russian Pharma Wholesale and Distribution Market: Revenue ($bn) Forecast, 2014-2024
Figure 4.33 Russian Pharma Wholesale and Distribution Market: Drivers and Restraints, 2014
Figure 5.1 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2013
Figure 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2018
Figure 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2024
Figure 5.4 Leading Pharmaceutical WandD Companies: Drivers and Restraints, 2013
Figure 5.5 McKesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2008-2013
Figure 5.6 McKesson: Revenue Share (%) Breakdown by Business Segment, 2013
Figure 5.7 McKesson: Gross Profit Share (%) Breakdown by Business Segment, 2013
Figure 5.8 McKesson: Revenue ($bn) Forecast, 2014-2024
Figure 5.9 McKesson: Drivers and Restraints, 2014-2024
Figure 5.10 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR (%), 2008-2013
Figure 5.11 Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2013
Figure 5.12 Cardinal Health: Gross Profit Share (%) Breakdown by Business Segment, 2013
Figure 5.13 Cardinal Health: Revenue Share (%) Breakdown by Customer, 2013
Figure 5.14 Cardinal Health: Revenue ($bn) Forecast, 2014-2024
Figure 5.15 Cardinal Health: Drivers and Restraints, 2014-2024
Figure 5.16 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2008-2013
Figure 5.17 AmerisourceBergen: Profit Share (%) Breakdown by Business Segment, 2013
Figure 5.18 AmerisourceBergen: Revenue ($bn) Breakdown by Customer, 2013
Figure 5.19 AmerisourceBergen: Revenue ($bn) Forecast, 2014-2024
Figure 5.20 AmerisourceBergen: Drivers and Restraints, 2014-2024
Figure 5.21 Alliance Boots: Historical Revenue (£bn), Revenue AGR (%), Trading Profit (£bn) and Gross Profit AGR (%), 2008-2013
Figure 5.22 Alliance Boots: Pharmaceutical Wholesale Revenue Share (%) Breakdown by Country, 2013
Figure 5.23 Alliance Boots: Revenue ($bn) Forecast, 2014-2024
Figure 5.24 Alliance Boots: Drivers and Restraints, 2014-2024
Figure 5.25 MEDIPAL Holdings: Historical Revenue (Â¥bn) Revenue AGR (%), Gross Profit (Â¥bn) and Gross Profit AGR (%), 2008-2013
Figure 5.26 MEDIPAL Holdings: Revenue Share (%) Breakdown by Business Segment, 2013
Figure 5.27 MEDIPAL Holdings: Operating Income Share (%) Breakdown by Business Segment, 2013
Figure 5.28 MEDIPAL Holdings: Revenue ($bn) Forecast, 2014-2024
Figure 5.29 MEDIPAL Holdings: Drivers and Restraints, 2014-2024
Figure 5.30 PHOENIX Group: Historical Revenue (€bn), Revenue AGR (%), Gross Profit (€bn) and Gross Profit AGR (%), 2008-2013
Figure 5.31 PHOENIX Group: Revenue Share (%) Breakdown by Region, 2013
Figure 5.32 PHOENIX Group: Revenue ($bn) Forecast, 2014-2024
Figure 5.33 PHOENIX Group Drivers and Restraints, 2014-2024
Figure 5.34 SINOPHARM Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2008-2013
Figure 5.35 SINOPHARM Group: Revenue ($bn) Forecast, 2014-2024
Figure 5.36 SINOPHARM Group: Drivers and Restraints, 2014-2024
Figure 5.37 Alfresa Holdings: Historical Revenue (Â¥bn), Revenue AGR (%), Gross Profit (Â¥bn) and Gross Profit AGR (%), 2008-2013
Figure 5.38 Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2013
Figure 5.39 Alfresa Holdings: Gross Profit Share (%) Breakdown by Business Segment, 2013
Figure 5.40 Alfresa Holdings: Revenue ($bn) Forecast, 2014-2024
Figure 5.41 Alfresa Holdings: Drivers and Restraints, 2014-2024
Figure 5.42 SUZUKEN: Historical Revenue (Â¥bn, $bn), Revenue AGR (%), Gross Profit (Â¥bn, $bn) and Gross Profit AGR (%), 2008-2013
Figure 5.43 SUZUKEN: Revenue Share (%) Breakdown by Business Segment, 2013
Figure 5.44 SUZUKEN: Operating Income Share (%) Breakdown by Business Segment, 2013
Figure 5.45 SUZUKEN: Revenue Share (%) Breakdown by Region in Japan, 2013
Figure 5.46 SUZUKEN: Revenue ($bn) Forecast, 2014-2024
Figure 5.47 SUZUKEN: Drivers and Restraints, 2014-2024
Figure 5.48 Shanghai Pharmaceuticals Holding: Historical Revenue (Â¥bn, $bn), Revenue AGR (%), Gross Profit (Â¥bn, $bn) and Gross Profit AGR (%), 2008-2013
Figure 5.49 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2013
Figure 5.50 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Region, 2013
Figure 5.51 Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2014-2024
Figure 5.52 Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2014-2024
Figure 6.1 Comparison of the Wholesale and DTP Routes of Distribution, 2014
Figure 6.2 Drug Pedigree Legislation: EU vs US, 2013
Figure 8.1 Pharmaceutical Wholesale and Distribution: Global Market Forecasts by Submarket, 2014-2024
Figure 8.2 Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections, 2013, 2018 and 2024
Figure 8.3 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($bn) Projections, 2013, 2018 and 2024

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.